pharmaphorum

OCTOBER 12, 2022

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.

Genome 96

Genome Genomics Medicine Development 96

World of DTC Marketing

DECEMBER 29, 2020

OBSERVATION: Biologics can take a long time to develop but COVID vaccines have been in development for almost 50 years and novel approaches were used to develop these vaccines. Vaccines typically take 10 to 15 years to develop, test and release to the public. The post How did pharma develop a vaccine so quickly?

Vaccination 307

Vaccination Vaccine Development Clinical Trials 307

pharmaphorum

SEPTEMBER 12, 2022

Alongside drugs and therapeutics, data collection and technology enhancements have redefined the traditional healthcare experience, especially within oncology, and genomic profiling has become a significant factor in allowing for personalised care. In other words, every person’s cancer has its own genetic construct. Tailored oncology.

Genome 103

Genome Genomics Clinical Trials Clinical Trials 103

pharmaphorum

JANUARY 18, 2023

In 2016, scientists behind a study called the Resilience Project analysed genetic data from 589,000+ people and found 13 adults who carried genetic variants that should have resulted in serious – even deadly – childhood disease, but who were apparently healthy. First, start co-development with participants early on in the process.

Genetic Disease 85

Genetic Disease Genetics Research Genome 85

Drug Discovery World

JANUARY 29, 2024

Leading experts in genomics, personalised medicine and drug discovery convened at the Precision Medicine Community Event in London to unveil the latest advancements shaping the future of healthcare. The post What are the key trends in genomics and precision medicine for 2024? appeared first on Drug Discovery World (DDW).

Genome 59

Genome Genomics Medicine Biobanking 59

Drug Discovery World

NOVEMBER 7, 2022

A new study led by Medical Research Council-funded researchers from UCL has found that tailoring the analysis of whole genome sequencing to individual patients could double the diagnostic rates of rare diseases. . Consequently, the UK has established itself at the forefront of diagnostic whole genome sequencing. Context .

Genome 52

Genome Genomics Genetics Genetic Disease 52

pharmaphorum

SEPTEMBER 14, 2020

Last week geneticist Dr Charles Steward shared with us his experiences of searching for a genetic cause for his children’s rare neurological diseases. Here he gives us a deeper look at how genomic medicine is evolving and the barriers that are preventing it from reaching its full potential.

Genome 111

Genome Genomics Medicine Gene 111

pharmaphorum

NOVEMBER 27, 2022

A group representing pharma companies selling precision therapies for cancer has called for a change to the way genomic testing is done in Scotland, to make sure patients get access to targeted drugs. “It would have saved me and the NHS a lot of money. .” Why do we always have to follow? Why not lead?”

Genome 89

Genome Genomics Genetics Medicine 89

Pharmaceutical Technology

DECEMBER 14, 2022

GSK has entered a strategic partnership with Wave Life Sciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. The alliance will merge the PRISM oligonucleotide platform of Wave and the capabilities of GSK in genetics and genomics.

Life Science 162

Life Science Development Gene Therapy Genetics 162

Drug Discovery World

MAY 5, 2023

Anthony Schmitt , PhD, Senior Vice President, Science at Arima Genomics, discusses the applications of 3D genomics in cancer research. But what about the patients whose genomic tests do not identify a cancer driver matched to an existing targeted therapy? with regards to detecting cancer driver mutations.

Genome 52

Genome Genomics Gene Genetics 52

Drug Discovery World

DECEMBER 13, 2022

PacBio, developer of sequencing solutions, has announced its HiFi sequencing technology will be used in a pilot project for the Children’s Rare Disease Cohorts Initiative (CRDC) at Boston Children’s Hospital. . The post Researchers investigate genetic variants linked to paediatric diseases appeared first on Drug Discovery World (DDW).

Genetics 52

Genetics Research Genome Genomics 52

Drug Discovery World

JUNE 19, 2023

PrecisionLife and Nanopharmaceutics have entered a strategic collaboration aiming to accelerate and de-risk the development of Nanopharmaceutics’ portfolio of central nervous system (CNS) assets.

Clinical Development 52

Clinical Development Development Clinical Trials Clinical Trials 52

Drug Discovery World

JUNE 21, 2023

The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Exact Sciences, Guardant Health, Illumina, MSD and Novartis have come together to launch the European Coalition for Access to Comprehensive Genomic Profiling (ECGP).

Genome 52

Genome Genomics Medicine Clinical Trials 52

pharmaphorum

SEPTEMBER 7, 2022

Pharma has a great opportunity ahead of it when it comes to conducting representative clinical trials. The industry’s application of mRNA techniques during the pandemic led to the fastest vaccine development in history. But our drug development processes are not perfect.

Clinical Trials 93

Clinical Trials Clinical Trials Trials Genetics 93

Drug Discovery World

OCTOBER 11, 2023

Gain Therapeutics has initiated a Phase I clinical trial of GT-02287, the company’s lead drug candidate for the treatment of GBA1 Parkinson’s disease. As an additional exploratory endpoint, this study will look at GCase target engagement and activity in blood for an early clinical validation of the effect of GT-02287 on GCase.

Genetics 72

Genetics Trials Clinical Trials Clinical Trials 72

Pharmaceutical Technology

JUNE 20, 2023

The Department of Health Abu Dhabi (DoH) has signed a memorandum of understanding with integrated healthcare company M42 and AbbVie Biopharmaceuticals to advance personalised medicine and genomics in the city. M42 was created through the combination of Mubadala Health and G42 Healthcare.

Medicine 130

Medicine Genome Genomics Clinical Trials 130

pharmaphorum

SEPTEMBER 16, 2022

With approximately one third of all current FDA-approved drugs targeting GPCRs, Verily/Sosei Heptares are looking to expedite GPCR research within not only immunology, but also gastroenterology and immuno-oncology as well, and the latest data bodes well for future development of therapeutic options in these areas.

Development 129

Development Research Drugs Clinical Trials 129

Drug Discovery World

JANUARY 26, 2023

DDW Editor Reece Armstrong takes a look at the pharmaceutical research and development market in 2023 and asks key opinion leaders what challenges and trends will emerge throughout the year. billion showed the pharma giant taking further steps into the oncology market and developing its speciality medicines vaccines portfolio.

Development 98

Development Drugs Clinical Trials Clinical Trials 98

Drug Discovery World

DECEMBER 5, 2022

A new partnership between industry and three rare disease foundations has formed with the goal of accelerating the development of precision drugs to treat rare neurodevelopmental disorders. . This lack of comprehensive data increases the risk of program failure in clinical trials. .

Development 52

Development Genome Genomics Drugs 52

Camargo

DECEMBER 10, 2021

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. Voxzogo’s approval was based on an intermediate clinical endpoint (though accelerated approvals can also come from surrogate endpoints ).

Development 176

Development Genetics Production Clinical Trials 176

XTalks

NOVEMBER 7, 2022

These tumor-derived entities are used to derive genomic and proteomic data. Gleich, MD, FACS, Senior Vice President, Medical Department, and Dr. Christopher Huth, PhD, Senior Clinical Trial Manager, Clinical Trial Management. Liquid Biopsy Use in Oncology Clinical Trials.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Drug Discovery World

FEBRUARY 6, 2024

Catherine Brownstein is an Assistant Professor in Pediatrics at Harvard Medical School and the Assistant Director of the Molecular Genetics Core Facility at Boston Children’s Hospital. Her current work focuses on advancing the fields of genome sequencing and analysis, with an emphasis on identifying complex structural variation.

Genome 59

Genome Genomics Genetics In-Vitro 59

Drug Discovery World

MARCH 27, 2023

Genomics is driving a revolution in drug development and, in the long run, the state of public healthcare. The first draft human genome took a decade to create, and 13 years to complete. Advances in sequencing are leading to scientific breakthroughs in preventative care, faster diagnoses, and proactive medical interventions.

Genome 52

Genome Genomics Research Scientist 52

Drug Discovery World

AUGUST 16, 2023

A new study has shed light on the genetic messages encoded by genes within ‘triple negative’ breast cancers (TNBC), and shows they could predict response to chemotherapy. The presence of these biomarkers could be used to accelerate the development of more personalised treatments for triple negative breast cancers.

Genetics 52

Genetics Gene Hormones RNA 52

Drug Discovery World

MARCH 2, 2023

By Lucy Radley, Head of EU Regulatory Development, ProPharma. Rare disease drugs can be complicated and expensive to produce, with a limited patient pool their development is often slow and their cost price to the UK’s health service high. Changing the business model behind drug development is the first step.

Development 52

Development Drugs Clinical Trials Clinical Trials 52

XTalks

APRIL 15, 2021

Late-stage clinical trial failures are largely to blame for the lack of effective treatment options for patients with HFpEF, and poor five-year survival rates make this an area of great unmet need. There are different subtypes of heart failure that have different clinical presentations.”. Heart failure affects about 6.2

Development 98

Development Drugs Genome Genomics 98

Drug Discovery World

OCTOBER 25, 2022

Scientists have shown how stomach cancers can develop resistance to a new class of drugs called ATR inhibitors by switching off the activity of two key genes – raising the possibility of outsmarting cancer by predicting drug resistance in advance. .

Development 52

Development Drugs Gene Editing Gene 52

XTalks

MARCH 7, 2024

Research at SRI International has highlighted the relationship between hormonal changes and sleep disruptions and developed systems to manage hot flashes. Experts discuss the therapeutic landscape, treatment gaps, regulatory considerations and clinical trial strategies.

Hormones 115

Hormones Genetics Genome Genomics 115

Drug Discovery World

DECEMBER 15, 2022

The R&D collaboration will leverage PrecisionLife’s combinatorial analytics-generated insights to identify novel therapeutic targets and patient stratification biomarkers in central nervous system (CNS) disorders for development by Ono. .

Clinical Trials 52

Clinical Trials Clinical Trials Genome Genomics 52

XTalks

DECEMBER 20, 2023

As we step into 2024, the life sciences continue to evolve at an unprecedented pace, driven by technological innovation, a deeper understanding of human biology and the application of new technologies in areas like drug development and health wearables. Regulatory bodies are also taking note of the applications of AI in drug development.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

XTalks

DECEMBER 1, 2020

Over the past several years, personalized medicine has led the charge in medical innovation, leading drug development efforts as well as furthering the research community’s understanding of human disease states. With this has come an increase in the size of the global clinical trials market, with an estimated worth of around $46.8

Clinical Trials 96

Clinical Trials Clinical Trials Trials Clinical Research 96

Drug Discovery World

MARCH 6, 2024

The development of effective new disease-modifying treatments in neurodegenerative and neuropsychiatric disorders has been hindered by their inherent genetic complexity, environmental influences, and clinical variability. This has been the real failure of some areas of CNS drug discovery.

Genome 64

Genome Genomics Clinical Trials Clinical Trials 64

pharmaphorum

MARCH 24, 2022

GlaxoSmithKline has thrown its financial and drug development weight behind LifeMine Therapeutics, a US startup that aims to find new therapeutics from fungi – widely regarded as an underexplored resource of biologically-active compounds. Greg Verdine – LifeMine. Image by jggrz from Pixabay .

Medicine 95

Medicine Genome Genomics Engineer 95

Drug Discovery World

MAY 17, 2024

Deepika Khedekar , Associate Centralized Clinical Trial Lead at IQVIA Inc, looks at the challenges of utilising artificial intelligence (AI) in oncology clinical research. MIT research 4 tells us a hard truth: about 95% of these trials fall short, leaving behind a trail of broken hopes for cancer patients each year.

Trials 59

Trials Clinical Trials Clinical Trials Protein 59

Drug Discovery World

DECEMBER 15, 2022

Gene editing tools such as zinc finger nucleases, transcription activator-like effector nucleases (TALEN) and clustered regularly interspaced short palindromic repeat (CRISPR) nucleases have been heralded for their enormous potential to treat diseases and genetic disorders. Early phase clinical trials for gene editing therapies.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

Scienmag

OCTOBER 28, 2020

Insights into why some people develop more severe symptoms than others and how to better treat the disease are desperately needed. The COVID-19 Host Genetics Initiative was created to study the relationship between variation in the human genome and SARS-CoV-2 infection. This is an […].

Genetics 40

Genetics Genome Genomics Development 40

Pharmaceutical Technology

FEBRUARY 15, 2023

Innovation S-curve for the pharmaceutical industry Gene splicing using nucleases is a key innovation area in the pharmaceutical industry Nucleases play a fundamental role in the field of recombinant DNA technology, or genetic engineering. Gene splicing using nucleases is used to design gene therapeutics for various genetic disorders.

Gene Splicing 130

Gene Splicing Gene Recombinant DNA Technology DNA 130